-
HDAC Inhibition Reverses EBV-Driven NPC Plasticity
2026-09-17
The reference study identifies an epigenetic mechanism by which EBV protein LMP1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. It further shows that HDAC inhibition can restore CEBPA expression and partially reverse this state in cellular and xenograft models, supporting differentiation therapy as a strategy for poorly differentiated solid tumors.
-
Pheromone-Driven Neurodegeneration in C. elegans
2026-09-17
Peng et al. show that early exposure to C. elegans pheromones can reprogram neurodevelopment and accelerate neurodegeneration later in life. The study connects combinatorial chemosensory signaling through ASK, ASI, and AIA interneurons with insulin-like signaling and reduced neuronal autophagy, offering a mechanistic framework for studying environmental effects on proteostasis.
-
Z-YVAD-FMK: Caspase-1 Inhibitor Workflow
2026-09-16
Build cleaner inflammasome, pyroptosis, and apoptosis experiments with a cell-permeable, irreversible caspase-1 inhibitor. This workflow combines practical dosing and handling guidance with assay choices informed by new evidence on chicken gasdermin cleavage.
-
Moxifloxacin Workflows for Antibiotic Toxicity
2026-09-15
Build reproducible Moxifloxacin assays that connect DNA gyrase inhibition with cellular viability, retinal ganglion cell responses, and acute metabolic endpoints. This guide combines practical dose-response design, mechanistic controls, and troubleshooting for antibiotic toxicity research.
-
S Tag Peptide: Practical Fusion-Tag Workflow
2026-09-15
S Tag Peptide is a compact, highly soluble fusion tag for recombinant protein detection, antibody-based capture, and protein solubility improvement. This guide covers construct design, aqueous handling, QC, and troubleshooting while clarifying that the peptide is not a standalone ribonuclease reagent and is unsuitable for ethanol-based protocols.
-
Nintedanib in ATRX-Deficient Glioma Research
2026-09-14
Learn how Nintedanib (BIBF 1120) can support genotype-aware glioma assays, RTK/PDGFR inhibitor screening, and combination studies with temozolomide. The workflow emphasizes solubility control, ATRX-stratified comparisons, mechanistic readouts, and practical troubleshooting.
-
Praeruptorin A: Applied Research Workflows
2026-09-14
Praeruptorin A connects inflammation, ferroptosis, cardiomyopathy, and cancer-invasion assays through experimentally testable pathways rather than a single endpoint. This workflow translates its STAT-1/3, DMT1, ERK1/2, and MMP1 biology into practical dosing, controls, troubleshooting, and translational decision points.
-
3X (DYKDDDDK) Peptide: Workflow Guide
2026-09-13
The 3X (DYKDDDDK) Peptide supports competitive elution, sensitive FLAG-fusion detection, and structurally informed protein workflows. This guide connects practical purification and assay decisions with lessons from a recent cryo-EM study of human PSS2.
-
GLI2, WNT, and Prostaglandins in Immunotherapy Resistance
2026-09-12
DeVito et al. identify GLI2 as a mechanistic coordinator linking mesenchymal transformation to WNT ligand production, prostaglandin signaling, and an immunosuppressive tumor microenvironment. The findings connect GLI2 activity with myeloid-derived suppressor cell recruitment, impaired cytotoxic lymphocyte function, and primary or adaptive resistance to anti-PD-1 therapy, providing a rationale for pathway-informed combination studies.
-
Atropo-Enantioselective Suzuki Synthesis: Rhazinilam Analog
2026-09-12
Herrbach and co-workers reported the first application of an asymmetric Suzuki cross-coupling to a biologically relevant axially chiral biaryl target. Screening and optimization of chiral phosphine ligands, particularly binaphthyl ligand 7a, furnished a nonbridged rhazinilam analogue precursor with up to 40% enantiomeric excess, establishing a catalytic route to the biologically relevant atropisomer.
-
NSC-23766: Rac1 Signaling Beyond Phagocytosis
2026-09-11
NSC-23766 is a Rac GTPase inhibitor that can help separate Rac-dependent cytoskeletal events from upstream immune-receptor signaling. This article translates recent CD47–Vav–Rac findings into practical assay design while defining the limits of extending Rac1 pharmacology to cancer and vascular models.
-
2-DG and the Metabolic-Epigenetic NSCLC Frontier
2026-09-11
A translational framework for using 2-Deoxy-D-glucose to interrogate glycolytic dependence, lactate-linked H3K18 lactylation, KRT19-driven senescence escape, and combination strategies in non-small cell lung cancer research.
-
Mubritinib–HSA Recognition: Methods and Findings
2026-09-10
The reference study clarifies how mubritinib interacts with human serum albumin through complementary fluorescence, biochemical, and molecular docking analyses. Its central contribution is linking moderate site I binding and local structural perturbation to inhibition of an HSA esterase-like function, providing a more pharmacologically meaningful view than affinity measurements alone.
-
SAR405: A Vps34 Probe for Nuclear PI3P
2026-09-10
SAR405 is a selective Vps34 inhibitor for dissecting autophagy, vesicle trafficking, and PI3P-dependent signaling. This article develops a compartment-aware assay framework linking Vps34 perturbation to nuclear DNA mismatch repair while distinguishing established evidence from testable hypotheses.
-
Gut Microbial H2S Suppresses GLP-1 in Male Mice
2026-09-09
This Nature Metabolism study identifies Desulfovibrio-derived hydrogen sulfide as a gut-to-host signal that impairs GLP-1 production by intestinal L cells through mitochondrial and unfolded-protein responses. Its mouse data connect microbial dysbiosis to metabolic dysfunction and show that bismuth subsalicylate can improve the phenotype, while also highlighting the need for sex-, species-, and mechanism-specific validation.